[go: up one dir, main page]

ES2037621A1 - Procedimiento para la preparacion de microesferas de material polimero biodegradable. - Google Patents

Procedimiento para la preparacion de microesferas de material polimero biodegradable.

Info

Publication number
ES2037621A1
ES2037621A1 ES929201522A ES9201522A ES2037621A1 ES 2037621 A1 ES2037621 A1 ES 2037621A1 ES 929201522 A ES929201522 A ES 929201522A ES 9201522 A ES9201522 A ES 9201522A ES 2037621 A1 ES2037621 A1 ES 2037621A1
Authority
ES
Spain
Prior art keywords
peptide
sustained
controlled release
composition
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES929201522A
Other languages
English (en)
Other versions
ES2037621B1 (es
Inventor
Piero Orsolini
Frederic Heimgarttner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debio Recherche Pharmaceutique SA
Original Assignee
Debio Recherche Pharmaceutique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debio Recherche Pharmaceutique SA filed Critical Debio Recherche Pharmaceutique SA
Publication of ES2037621A1 publication Critical patent/ES2037621A1/es
Application granted granted Critical
Publication of ES2037621B1 publication Critical patent/ES2037621B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE MICROESFERAS DE MATERIAL POLIMERO BIODEGRADABLE PARA LA CONSTITUCION DE UNA COMPOSICION DESTINADA A LA LIBERACION PROLONGADA Y CONTROLADA DE SUSTANCIAS MEDICAMENTOSAS PEPTIDICAS, INCORPORANDO DICHAS MICROESFERAS DICHA SUBSTANCIA MEDICAMENTOSA. CONSISTE EL PROCEDIMIENTO EN CONVERTIR PRIMERAMENTE UN PEPTIDO O SAL DE PEPTIDO SOLUBLE EN EL AGUA EN UN PEPTIDO, RESPECTIVAMENTE UNA SAL DE PEPTIDO, INSOLUBLE EN EL AGUA. LAS ETAPAS SUBSIGUIENTES RECURREN A CONTINUACION A LA PREPARACION DE UNA EMULSION ORGANICA ACUOSA, Y DESPUES A LA EXTRACCION DEL SOLVENTE ORGANICO EN UN EXCESO DE MEDIO ACUOSO.
ES9201522A 1991-07-22 1992-07-21 Procedimiento para la preparacion de microesferas de material polimero biodegradable. Expired - Fee Related ES2037621B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2178/91A CH683149A5 (fr) 1991-07-22 1991-07-22 Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Publications (2)

Publication Number Publication Date
ES2037621A1 true ES2037621A1 (es) 1993-06-16
ES2037621B1 ES2037621B1 (es) 1994-02-01

Family

ID=4227716

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09201523A Expired - Fee Related ES2050070B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.
ES9201522A Expired - Fee Related ES2037621B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de microesferas de material polimero biodegradable.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09201523A Expired - Fee Related ES2050070B1 (es) 1991-07-22 1992-07-21 Procedimiento para la preparacion de una composicion destinada a la liberacion prolongada y controlada de una substancia peptidica.

Country Status (40)

Country Link
US (2) US5445832A (es)
JP (2) JP2842736B2 (es)
KR (1) KR930702018A (es)
CN (1) CN1054543C (es)
AT (2) AT403348B (es)
AU (2) AU651711B2 (es)
BE (2) BE1005696A3 (es)
BR (1) BR9205375A (es)
CA (2) CA2074320C (es)
CH (2) CH683149A5 (es)
CZ (1) CZ287585B6 (es)
DE (3) DE4223282A1 (es)
DK (2) DK176219B1 (es)
EE (1) EE03014B1 (es)
ES (2) ES2050070B1 (es)
FI (2) FI106925B (es)
FR (2) FR2679450B1 (es)
GB (2) GB2257909B (es)
GR (2) GR1002548B (es)
HR (1) HRP920229A2 (es)
HU (1) HU218203B (es)
IE (2) IE71199B1 (es)
IL (2) IL102591A (es)
IT (2) IT1259891B (es)
LU (2) LU88150A1 (es)
MX (1) MX9204268A (es)
NL (2) NL194576C (es)
NO (2) NO304057B1 (es)
NZ (1) NZ243643A (es)
PH (1) PH31564A (es)
PL (1) PL169387B1 (es)
PT (2) PT100713B (es)
RU (1) RU2103994C1 (es)
SE (2) SE512670C2 (es)
SI (1) SI9200152B (es)
SK (1) SK280612B6 (es)
TW (1) TW260610B (es)
UA (1) UA35569C2 (es)
WO (1) WO1993001802A1 (es)
ZA (2) ZA925485B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169980A1 (es) * 1999-12-17 2002-07-16 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
JP2944419B2 (ja) 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト 持続性遊離組成物中の薬理学的活性成分の安定
DE4320201A1 (de) * 1993-06-18 1995-01-12 Asta Medica Ag Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR0162872B1 (ko) * 1996-04-01 1998-12-01 김은영 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법
US20020111603A1 (en) * 1996-12-02 2002-08-15 Societe De Conseils De Recherches Et D'application Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6465015B1 (en) * 1998-02-24 2002-10-15 Arch Chemicals, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
CA2324254C (en) * 1998-03-18 2005-01-04 University Technology Corporation Sustained-release composition including amorphous polymer
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
ES2185373T3 (es) * 1998-07-23 2003-04-16 Sod Conseils Rech Applic Encapsulacion de peptidos solubles en agua.
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6682724B2 (en) 1999-02-23 2004-01-27 Arch Chemcials, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6317623B1 (en) * 1999-03-12 2001-11-13 Medrad, Inc. Apparatus and method for controlling contrast enhanced imaging procedures
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309454B1 (en) 2000-05-12 2001-10-30 Johnson & Johnson Medical Limited Freeze-dried composite materials and processes for the production thereof
AU2002235253A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophilic active agents
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
BR0212833A (pt) * 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
KR100885070B1 (ko) * 2002-05-08 2009-02-25 재단법인서울대학교산학협력재단 Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7314859B2 (en) * 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
ES2350123T3 (es) 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004218369A1 (en) * 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
PT1682537E (pt) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Moduladores de adesão celular
RU2527893C2 (ru) 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006078903A1 (en) * 2005-01-21 2006-07-27 Matthews Richard H Radiosensitizer formulations comprising nitrohistidine derivatives
CA2605000A1 (en) * 2005-04-25 2006-11-02 Amgen Inc. Biodegradable peptide sustained release compositions containing porogens
CA2960117C (en) 2005-05-17 2018-01-30 Sarcode Bioscience Inc. Lfa-1 antagonists for the treatment of eye disorders
KR20080027340A (ko) * 2005-06-14 2008-03-26 백스터 인터내셔널 인코포레이티드 약물-약물 상호작용을 최소화하기 위한 제약학적 제형
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
KR101458728B1 (ko) 2005-12-22 2014-11-05 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
WO2007089739A2 (en) 2006-01-27 2007-08-09 Stryker Corporation Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
RU2326655C1 (ru) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA019284B1 (ru) * 2007-06-06 2014-02-28 Дебиофарм Рисёрч Энд Мэньюфэкчуринг Са Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
US20090258069A1 (en) * 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
MX2011009503A (es) 2009-03-09 2011-09-28 Pronova Biopharma Norge As Composiciones que comprenden una mezcla de aceite de acido graso y un tensioactivo, y metodos y usos de las mismas.
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
SG181446A1 (en) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Combination composition useful for treating cardiovascular diseases
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2705013B1 (en) 2011-05-04 2016-03-30 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
ES2606392T3 (es) 2012-04-04 2017-03-23 Pronova Biopharma Norge As Composiciones que comprenden ácidos grasos omega-3 y vitamina D para acné vulgar y/o eccema, y procedimientos y usos de las mismas
IN2014DN09621A (es) * 2012-05-14 2015-07-31 Teijin Ltd
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014222389B2 (en) 2013-02-28 2018-11-29 Pronova Biopharma Norge As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
WO2015054649A2 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
KR102644400B1 (ko) 2015-04-28 2024-03-06 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
JOP20200068A1 (ar) 2017-09-26 2020-04-27 Nanomi B V طريقة لتحضير جسيمات دقيقة بواسطة تقنية مستحلب مزدوج
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292710A2 (en) * 1987-05-26 1988-11-30 American Cyanamid Company Hardening agent for phase separation microencapsulation
ES2009346A6 (es) * 1987-09-21 1989-09-16 Debiopharm Sa Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
ES2009347A6 (es) * 1987-10-14 1989-09-16 Debiopharm Sa Procedimiento para la preparacion de una composicion farmaceutica.
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
JPS523342B2 (es) * 1972-01-26 1977-01-27
US3976071A (en) * 1974-01-07 1976-08-24 Dynatech Corporation Methods of improving control of release rates and products useful in same
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
CH679207A5 (es) * 1989-07-28 1992-01-15 Debiopharm Sa
CH681425A5 (es) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292710A2 (en) * 1987-05-26 1988-11-30 American Cyanamid Company Hardening agent for phase separation microencapsulation
ES2009346A6 (es) * 1987-09-21 1989-09-16 Debiopharm Sa Procedimiento de preparacion de composiciones farmaceuticas que contienen polipeptidos hidroinsolubles.
ES2009347A6 (es) * 1987-10-14 1989-09-16 Debiopharm Sa Procedimiento para la preparacion de una composicion farmaceutica.
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169980A1 (es) * 1999-12-17 2002-07-16 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US9789064B2 (en) 1999-12-17 2017-10-17 Gp Pharm, S.A. Method for delivering a peptide to a subject at a modulated rate via microcapsules of lactic-co-glycolic copolymer containing said peptide

Also Published As

Publication number Publication date
CH683149A5 (fr) 1994-01-31
GB2257973A (en) 1993-01-27
NL194576C (nl) 2002-08-05
NO304136B1 (no) 1998-11-02
DK176219B1 (da) 2007-02-26
AU2043792A (en) 1993-01-28
ATA148892A (de) 2001-06-15
CN1070344A (zh) 1993-03-31
NL194576B (nl) 2002-04-02
BE1005697A5 (fr) 1993-12-21
MX9204268A (es) 1994-03-31
AU651711B2 (en) 1994-07-28
DK176218B1 (da) 2007-02-26
CH683592A5 (fr) 1994-04-15
RU2103994C1 (ru) 1998-02-10
HUT64234A (en) 1993-12-28
PT100712A (pt) 1993-10-29
DE9219084U1 (de) 1997-09-25
FI923321A0 (fi) 1992-07-21
ITBS920093A1 (it) 1994-01-21
SK38293A3 (en) 1993-08-11
IT1259891B (it) 1996-03-28
GB2257973B (en) 1996-02-28
HU218203B (hu) 2000-06-28
SE9202213L (sv) 1993-01-23
ATA148992A (de) 1997-06-15
SE9202212D0 (sv) 1992-07-21
NO922885L (no) 1993-01-25
JP2842736B2 (ja) 1999-01-06
IL102591A (en) 1997-06-10
FI923320A0 (fi) 1992-07-21
ITBS920092A0 (it) 1992-07-21
PL169387B1 (pl) 1996-07-31
CZ66093A3 (en) 1994-01-19
FR2679450A1 (fr) 1993-01-29
DK93892A (da) 1993-01-23
HU9301186D0 (en) 1993-07-28
FR2680109A1 (fr) 1993-02-12
IL102590A (en) 1997-07-13
NZ243643A (en) 1993-10-26
IT1259892B (it) 1996-03-28
GR920100323A (el) 1993-05-24
HRP920229A2 (en) 1996-04-30
AU652844B2 (en) 1994-09-08
DE4223284A1 (de) 1993-01-28
DK93892D0 (da) 1992-07-21
SE9202212L (sv) 1993-01-23
DE4223282A1 (de) 1993-01-28
ES2050070A1 (es) 1994-05-01
FI923320L (fi) 1993-01-23
FI105318B (fi) 2000-07-31
IE922367A1 (en) 1993-01-27
FR2680109B1 (fr) 1994-09-02
KR930702018A (ko) 1993-09-08
WO1993001802A1 (fr) 1993-02-04
SK280612B6 (sk) 2000-05-16
CA2074320A1 (en) 1993-01-23
BR9205375A (pt) 1994-03-08
IE922366A1 (en) 1993-01-27
ES2050070B1 (es) 1994-10-01
NL194577C (nl) 2002-08-05
UA35569C2 (uk) 2001-04-16
TW260610B (es) 1995-10-21
GB2257909A (en) 1993-01-27
PH31564A (en) 1998-11-03
SE9202213D0 (sv) 1992-07-21
SI9200152A (en) 1993-03-31
NL9201310A (nl) 1993-02-16
DK93992D0 (da) 1992-07-21
NO922886D0 (no) 1992-07-21
JP3600252B2 (ja) 2004-12-15
US5637568A (en) 1997-06-10
GB9215480D0 (en) 1992-09-02
NO922886L (no) 1993-01-25
ES2037621B1 (es) 1994-02-01
GB2257909B (en) 1996-01-10
AT403348B (de) 1998-01-26
IE71199B1 (en) 1997-02-12
CA2074322C (en) 2003-04-08
PT100713A (pt) 1993-08-31
PT100713B (pt) 1999-07-30
DE4223284C2 (de) 1997-07-31
PT100712B (pt) 1999-07-30
NO304057B1 (no) 1998-10-19
BE1005696A3 (fr) 1993-12-21
NO922885D0 (no) 1992-07-21
JPH06172208A (ja) 1994-06-21
FI923321L (fi) 1993-01-23
GR1001446B (el) 1993-12-30
CA2074320C (en) 1999-04-06
DK93992A (da) 1993-01-23
NL9201309A (nl) 1993-02-16
PL298504A1 (en) 1994-01-10
ZA925486B (en) 1993-04-28
FR2679450B1 (fr) 1995-06-09
SE512609C2 (sv) 2000-04-10
LU88151A1 (fr) 1993-02-15
JPH05221855A (ja) 1993-08-31
US5445832A (en) 1995-08-29
IE69967B1 (en) 1996-10-16
CZ287585B6 (cs) 2000-12-13
CN1054543C (zh) 2000-07-19
ZA925485B (en) 1993-04-28
AU2043692A (en) 1993-01-28
SI9200152B (sl) 1998-06-30
CA2074322A1 (en) 1993-01-23
GR1002548B (el) 1997-01-28
NL194577B (nl) 2002-04-02
IL102590A0 (en) 1993-01-14
GB9215479D0 (en) 1992-09-02
SE512670C2 (sv) 2000-04-17
LU88150A1 (fr) 1993-02-15
EE03014B1 (et) 1997-08-15
ITBS920092A1 (it) 1994-01-21
AT408609B (de) 2002-01-25
ITBS920093A0 (it) 1992-07-21
FI106925B (fi) 2001-05-15
IL102591A0 (en) 1993-01-14

Similar Documents

Publication Publication Date Title
ES2037621A1 (es) Procedimiento para la preparacion de microesferas de material polimero biodegradable.
ATE154822T1 (de) Präparate von fettlöslichen substanzen
NL195027B (nl) Werkwijze voor het bereiden van microdeeltjes voor langzame afgifte van in water oplosbare peptiden en preparaten daarvan.
DK0737064T3 (da) Fremgangsmåde til fremstilling af faste farmaceutiske doseringsformer af hydrofobe stoffer
GB2186485B (en) Slow release formulation
AU3772693A (en) Super porous polysaccharide gels
DK0737065T3 (da) Fremgangsmåde til fremstilling af faste farmaceutiske doseringsformer
CA2223427A1 (en) Collagen-based delivery matrix
NO982364L (no) FremgangsmÕte for fremstilling av morfologisk anhetlige mikrokapsler, samt mikrokapsler fremstilt ved fremgangsmÕten
ES2113095T3 (es) Preparacion solida de liberacion rapida, su produccion y su uso.
AU4807197A (en) Hydrophilic microparticles and methods to prepare same
KR970703133A (ko) 중합체 매트릭스 중의 활성제의 고용체 형태로서의 활성제 제제의 제조 방법 및 그에 의해 얻어진 활성제 제제(Process for Producing Active Agent Preparations in the Form of a Solid Solution of the Active Agent in a Polymer Matrix and Active Agent Preparations Obtained Thereby)
UA40634C2 (uk) Мікрокапсула, яка містить суспензію твердої біологічно активної сполуки, і спосіб її одержання
NL194858B (nl) Werkwijze voor de bereiding van een farmaceutisch preparaat in de vorm van microdeeltjes, en een werkwijze voor de bereiding van farmaceutisch preparaat in de vorm van een injecteerbare suspentie van microdeeltjes.
AU5979186A (en) Time-controlled exploding systems and processes for preparing the same
GR3018970T3 (en) Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions.
NO904754L (no) Kapsel for innkapsling av biologisk aktive materialer, fremgangsmaate for fremstilling av denne, samt anvendelse derav.
KR890007789A (ko) 수용성 펩타이드 및 단백질의 생체분해 가능한 마이크로캡슐의 제조방법 및 이 방법에 의해 수득되는 마이크로캡슐
AU4765999A (en) Polyionic hydrogels based on xanthan and chitosan for stabilising and controlledrelease of vitamins
AP9801415A0 (en) A method of making a liquid fertilizing substance.

Legal Events

Date Code Title Description
FD2A Announcement of lapse in spain

Effective date: 20141120